Gilead Sciences, Inc.

While Gilead Sciences has seen softening of sales for its approved oncology products, the company is nevertheless showing momentum in its oncology pipeline, particularly for the CAR-T cell therapy ani

Gilead Sciences does not anticipate that realized or potential cuts at the US Department of Health and Human Services, the Centers for Disease Control and Prevention and the Food and Drug Administrati

Galapagos revealed its second leadership transition in as many weeks on 22 April, reporting that CEO Paul Stoffels plans to retire from the company upon the appointment of a new chief executive, who w

Gilead Sciences is looking to expand the reach of Trodelvy (sacituzumab govitecan-hziy) into the frontline setting of triple-negative breast cancer (TNBC) based on positive topline results in combinat